药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02269 药明生物

未开盘 07-13 16:08:41

37.320

-0.640

-1.69%

最高38.680	最低36.920	成交量2,503万
今开37.900	昨收37.960	日振幅4.64%
总市值1,547亿	流通市值1,547亿	总股本41.44亿
成交额9.39亿	换手率0.60%	流通股本41.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":37.32,"timestamp":1783930121003,"preClose":37.96,"halted":0,"volume":25025310,"delay":0,"changeRate":-0.01685985247629085,"floatShares":4144000000,"shares":4144000000,"eps":1.3409005270468353,"marketStatus":"未开盘","change":-0.64,"latestTime":"07-13 16:08:41","open":37.9,"high":38.68,"low":36.92,"amount":939062630,"amplitude":0.046365,"askPrice":37.32,"askSize":11500,"bidPrice":37.3,"bidSize":18500,"shortable":3,"etf":0,"ttmEps":1.3409005270468353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783992600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":37.96,"openAndCloseTimeList":[[1783906200000,1783915200000],[1783918800000,1783929600000]],"volumeRatio":0.625162124826776,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.5956,"impliedVolPercentile":0.9265},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU0455707207.USD","BK1515","BK1161","IE00B5MMRT66.SGD","LU0359201612.USD","06160","LU1969619763.USD","IE0008369823.USD","02269","LU0067412154.USD","LU0501845795.SGD","BD","LU2097828474.EUR","LU0051755006.USD","MEDX","159992","LU0456846285.SGD","LU0348825331.USD","LU1807302812.USD","KURE","LU2488822045.USD","KCE","06185","IE0008368742.USD","LU1961090484.USD","IE00B0JY6N72.USD","LU0359202008.SGD","LU1688375341.USD","01877","01801","LU2097828631.EUR","01177","LU0348784397.USD","LU1813983027.USD","06978","02616","09688","BK1588","IBBQ","LU1960683339.HKD","LU2242644610.SGD","LU0348735423.USD","02142","601066","LU0516422366.SGD","LU1226288170.HKD","LU1993786604.SGD","01093","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159355840","title":"异动解读｜药明生物盘中上涨3.45%，MFG8原料药设施获FDA批准持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1159355840","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159355840?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:50","pubTimestamp":1783648249,"startTime":"0","endTime":"0","summary":"7月10日，药明生物盘中上涨3.45%，报38.34港元/股，成交额1.4亿港元。消息面上，公司旗下MFG8原料药生产设施成功获得美国FDA上市批准前检查批准，为一种潜在重磅自身免疫疗法实现商业化供应迈出关键一步。该认证验证了设施符合国际高标准生产质量体系，为后续大规模稳定药品生产铺平道路，相关疗法上市进程有望加速。瑞银此前上调公司目标价至51.1港元并维持买入评级，当前股价仍有较大折让空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121745953","title":"药明生物MFG8原料药设施获FDA Pli批准，助推潜在重磅自身免疫疗法商业化供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1121745953","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121745953?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:32","pubTimestamp":1783582335,"startTime":"0","endTime":"0","summary":"药明生物旗下MFG8原料药生产设施成功获得美国食品药品监督管理局的Pli批准，此举标志着公司为一种潜在的重磅自身免疫疗法实现商业化供应迈出了关键一步。该认证的取得，不仅验证了设施符合国际高标准的生产质量体系，也为后续大规模、稳定的药品生产铺平了道路。随着监管门槛的跨越，相关疗法的上市进程有望加速，满足未来巨大的市场需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU3063872942.SGD","LU0708995583.HKD","LU0456827905.SGD","LU1720050803.USD","BK1610","BK1576","LU0320764599.SGD","BK1589","LU0359202008.SGD","LU0348825331.USD","IE00B0JY6N72.USD","LU1688375341.USD","LU0856984785.SGD","LU0516422440.USD","BK1141","LU0327786744.USD","LU0516422366.SGD","LU0052750758.USD","LU0043850808.USD","LU0516423174.USD","LU1794554557.SGD","LU0307460666.USD","LU0819121731.USD","SG9999002562.SGD","LU0979878070.USD","LU1242518857.USD","LU0326950275.SGD","LU0359201612.USD","LU0348735423.USD","LU0417516902.SGD","LU0516422952.EUR","02269","LU0417516738.SGD","LU0039217434.USD","LU0823426480.USD","KURE","LU0456846285.SGD","BK1521","LU1880383366.USD","LU0588546209.SGD","SG9999002463.SGD","LU1242518931.SGD","LU0140636845.USD","LU0181495838.USD","LU0516423091.SGD","LU0572944931.SGD","LU0051755006.USD","LU2039709279.SGD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910638","title":"港股异动 | 药明生物(02269.HK)早盘涨超6% MFG8原液生产厂通过美国FDA上市批准前检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910638","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650910638?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:13","pubTimestamp":1783563221,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","LU0359202008.SGD","LU0456846285.SGD","SG9999002562.SGD","BK1576","02269","LU0052750758.USD","LU0516422366.SGD","LU0823426480.USD","LU1794554557.SGD","LU0708995583.HKD","LU2039709279.SGD","LU0359201612.USD","LU0516423091.SGD","LU0856984785.SGD","LU0572944931.SGD","LU0326950275.SGD","KURE","LU0819121731.USD","SG9999002463.SGD","LU0417516738.SGD","LU0516422952.EUR","BK1521","LU0181495838.USD","LU0417516902.SGD","LU0588546209.SGD","LU0456827905.SGD","LU0979878070.USD","LU0516423174.USD","LU0307460666.USD","IE00B0JY6N72.USD","LU1242518857.USD","LU1242518931.SGD","LU1688375341.USD","LU0516422440.USD","LU0320764599.SGD","LU0051755006.USD","LU0140636845.USD","LU0348735423.USD","LU1720050803.USD","LU0327786744.USD","LU0039217434.USD","BK1589","LU0823426308.USD","LU0043850808.USD","LU3063872942.SGD","LU0348825331.USD","BK1610","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180230232","title":"异动解读｜药明生物盘中上涨3.03%，板块反弹叠加持续高频回购提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1180230232","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180230232?lang=zh_cn&edition=full","pubTime":"2026-07-09 09:53","pubTimestamp":1783561998,"startTime":"0","endTime":"0","summary":"7月9日，药明生物盘中上涨3.03%，报37.2港元/股，成交额2.54亿港元。消息面上，此前连续两日走弱的生命科学工具和服务板块集体反弹，英矽智能涨7.46%、药明合联涨3.52%、晶泰控股涨2.34%、药明康德涨2.12%，板块共振效应显著。公司维持高频回购节奏，7月7日再度斥资约9982万港元回购271.65万股，年内累计回购金额达12.72亿港元。此外，瑞银此前上调公司目标价至51.1港元并维持买入评级，当前股价较目标价仍有约27%的折让空间。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181293986","title":"异动解读｜药明生物盘中下跌3.05%，生命科学板块连续走弱拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1181293986","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181293986?lang=zh_cn&edition=full","pubTime":"2026-07-08 14:56","pubTimestamp":1783493792,"startTime":"0","endTime":"0","summary":"7月8日，药明生物盘中下跌3.05%，报35.66港元/股，成交额9.42亿港元。消息面上，生命科学工具和服务板块连续第二日普遍走弱，药明康德跌3.33%，药明合联跌3.88%，金斯瑞生物科技跌1.33%，晶泰控股跌1.41%，板块共振效应显著。此前瑞银上调公司目标价至51.1港元并维持买入评级，当前股价较目标价仍有较大折让。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU0326950275.SGD","01952","KURE","MEDX","LU2242644610.SGD","LU0516423091.SGD","02186","LU0051755006.USD","159992","BK1600","LU0052750758.USD","LU1046422090.SGD","06955","IE00B0JY6N72.USD","LU0196878994.USD","01672","BK1583","SG9999014674.SGD","LU0819121731.USD","LU1880383366.USD","SG9999002463.SGD","CZA","06855","01530","LU0348784397.USD","00460","LU0417516571.SGD","BK1191","LU2476274308.USD","LU0348783233.USD","LU0588546209.SGD","LU0516422440.USD","02269","09926","01477","LU3063872942.SGD","02268","LU0572944931.SGD","LU0140636845.USD","LU0456846285.SGD","LU0979878070.USD","REVS","02359","IBBQ","BK1521","06978","LU0320764599.SGD","BK1141","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121511179","title":"药明生物7月7日回购271.65万股，耗资约9,982.33万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121511179","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121511179?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:55","pubTimestamp":1783432540,"startTime":"0","endTime":"0","summary":"根据公告，公司于2026年7月2日至7月7日期间，因行使2016年1月5日采纳的首次公开发售前购股权计划，共发行普通股206,000股，发行价介乎每股港币1.86至2.19元。受此影响，公司已发行股本由2026年6月30日的4,143,356,617股增至4,143,562,617股。此外，药明生物于2026年7月7日于香港联交所回购普通股2,716,500股，占前一交易日已发行股本约0.06556%，最高回购价为每股港币36.88元，最低回购价为每股港币36.56元，涉及总金额约9,982.33万港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物7月7日回购271.65万股，耗资约9,982.33万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649336019","title":"药明生物(02269)7月7日斥资约9982.33万港元回购271.65万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649336019","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649336019?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:52","pubTimestamp":1783432359,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明生物(02269)发布公告，于2026年7月7日该公司斥资约9982.33万港元回购271.65万股，回购价格为每股36.56至36.88港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422440.USD","LU3063872942.SGD","LU0359202008.SGD","LU0823426308.USD","BK1589","LU0052750758.USD","LU0307460666.USD","LU0348825331.USD","LU0572944931.SGD","LU0516423174.USD","LU0823426480.USD","LU2039709279.SGD","BK1576","LU0320764599.SGD","LU0043850808.USD","LU0856984785.SGD","LU0140636845.USD","SG9999002562.SGD","LU0326950275.SGD","LU0359201612.USD","LU0588546209.SGD","LU0348735423.USD","LU0708995583.HKD","LU1794554557.SGD","LU0327786744.USD","LU0051755006.USD","LU0039217434.USD","LU0516423091.SGD","LU1720050803.USD","KURE","LU0819121731.USD","LU0456827905.SGD","LU1242518857.USD","LU0456846285.SGD","BK1610","LU0417516738.SGD","LU1242518931.SGD","LU1688375341.USD","LU0181495838.USD","BK1141","LU0979878070.USD","SG9999002463.SGD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0417516902.SGD","BK1521","02269","LU1880383366.USD","LU0516422952.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164093918","title":"异动解读｜药明生物盘中下跌3.02%，报36.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164093918","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164093918?lang=zh_cn&edition=full","pubTime":"2026-07-07 13:59","pubTimestamp":1783403967,"startTime":"0","endTime":"0","summary":"7月7日，药明生物盘中下跌3.02%，报36.66港元/股，成交额5.57亿港元。药明生物所在的生命科学工具和服务行业中，个股普遍走弱，药明康德跌3.41%，英矽智能跌4.02%，晶泰控股跌4.64%，药明合联跌3.62%，康龙化成涨0.54%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139410800","title":"药明生物6月股份变动月报表：已发行股份增至4,143,356,617股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139410800","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139410800?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:41","pubTimestamp":1783330897,"startTime":"0","endTime":"0","summary":"药明生物技术有限公司于2026年7月6日披露截至2026年6月30日的股份变动月报表。公告显示，公司法定注册股本维持在6,000,000,000股普通股不变，面值为每股USD 0.000008333333，总注册股本折合USD 50,000，较上个月无变动。根据公告，药明生物本月新增已发行股份2,446,181股，主要来源于若干首次公开发售前购股权计划的行使，共带来USD 569,217.16的认股资金。截至报告期末，公司已发行股份由上月的4,140,910,436股增至4,143,356,617股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172876476","title":"异动解读｜药明生物盘中上涨3.09%，持续高频回购叠加板块共振走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1172876476","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172876476?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:12","pubTimestamp":1783303962,"startTime":"0","endTime":"0","summary":"7月6日，药明生物盘中上涨3.09%，报38.72港元/股，成交额3.52亿港元。消息面上，公司维持高频回购节奏，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司内在价值的信心。此外，公司近日宣布无锡生产基地三家工厂以\"零发现项\"通过巴西ANVISA GMP认证，进一步验证其全球商业化生产能力。板块方面，生命科学工具和服务行业个股普遍走强，金斯瑞生物科技涨6.1%、药明合联涨6.0%、晶泰控股涨4.18%，板块共振效应显著。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648365531","title":"瑞银：升药明生物(02269.HK)目标价至51.1港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648365531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648365531?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:36","pubTimestamp":1783056983,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320764599.SGD","LU0326950275.SGD","LU1794554557.SGD","LU0307460666.USD","LU0708995583.HKD","SG9999002463.SGD","LU0823426308.USD","LU0516423174.USD","LU0043850808.USD","LU0823426480.USD","LU0856984785.SGD","LU3063872942.SGD","LU0516422952.EUR","LU0327786744.USD","LU0417516738.SGD","LU1242518931.SGD","BK1589","LU0140636845.USD","BK1141","LU1880383366.USD","LU0516422440.USD","LU0516423091.SGD","SG9999002562.SGD","BK1576","IE00B0JY6N72.USD","LU0359202008.SGD","LU0348735423.USD","LU1720050803.USD","LU0572944931.SGD","LU2039709279.SGD","LU0039217434.USD","LU1688375341.USD","LU0588546209.SGD","LU0456827905.SGD","LU1242518857.USD","LU0052750758.USD","LU0348825331.USD","LU0819121731.USD","BK1521","LU0359201612.USD","LU0456846285.SGD","LU0516422366.SGD","BK1610","02269","LU0181495838.USD","LU0417516902.SGD","LU0051755006.USD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190087325","title":"异动解读｜药明生物盘中上涨3.4%，持续高频回购叠加巴西GMP认证提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1190087325","media":"行情直击","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190087325?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:27","pubTimestamp":1783056441,"startTime":"0","endTime":"0","summary":"7月3日，药明生物盘中上涨3.4%，报37.08港元/股，成交额8.24亿港元。消息面上，公司维持高频回购节奏，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司价值的信心。此外，公司近日宣布无锡生产基地三家工厂以\"零发现项\"通过巴西ANVISA GMP认证，进一步验证全球商业化生产能力。板块方面，生命科学工具和服务行业个股走强，药明合联涨5.02%、金斯瑞生物科技涨2.59%、晶泰控股涨3.48%，板块共振效应显著。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02269","LU2097828714.EUR","LU2097828805.USD","01877","LU0072913022.USD","09688","LU1226287792.SGD","LU2476274720.SGD","LU0348766576.USD","IE0008369823.USD","LU0315179316.USD","09926","LU2778985437.USD","601066","IE00B5MMRT66.SGD","02142","LU0856984785.SGD","01801","IE00B031HY20.USD","LU1226287875.USD","LU2097828631.EUR","159992","06160","LU2039709279.SGD","01177","LU1242518931.SGD","LU0516422366.SGD","01093","SG9999004220.SGD","06185","LU0417516738.SGD","LU0501845795.SGD","LU1688375341.USD","LU0979878070.USD","LU0043850808.USD","BK1589","LU0502904849.HKD","LU2476274308.USD","01477","LU1969619763.USD","02616","LU3063872942.SGD","LU2488822045.USD","LU0456846285.SGD","LU1961090484.USD","LU0067412154.USD","HK0000165453.HKD","06978","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114554418","title":"异动解读｜药明生物盘中上涨3.47%，持续高频回购叠加获巴西GMP认证提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1114554418","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114554418?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:10","pubTimestamp":1782958206,"startTime":"0","endTime":"0","summary":"7月2日，药明生物盘中上涨3.47%，报35.92港元/股，成交额5.09亿港元。消息面上，公司近期维持高频回购节奏，6月30日斥资约9982.5万港元回购289万股，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司价值的信心。此外，公司近日宣布其无锡生产基地三家工厂以\"零发现项\"通过巴西ANVISA GMP认证，进一步验证全球商业化生产能力。板块方面，生命科学工具和服务行业个股走强，药明合联涨3.68%、金斯瑞生物科技涨4.33%，板块共振效应显著。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647552508","title":"药明生物(02269.HK)6月30日斥资9982.5万港元回购289万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647552508","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647552508?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:24","pubTimestamp":1782829442,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0326950275.SGD","LU0039217434.USD","BK1521","LU1242518857.USD","LU0588546209.SGD","02269","SG9999002463.SGD","LU0516422440.USD","LU0819121731.USD","LU1720050803.USD","LU0348735423.USD","LU1242518931.SGD","LU0516422952.EUR","LU0052750758.USD","LU0051755006.USD","BK1141","LU0708995583.HKD","LU0516422366.SGD","LU0823426480.USD","LU2039709279.SGD","LU0516423174.USD","LU0140636845.USD","LU0516423091.SGD","BK1610","LU0181495838.USD","LU0417516902.SGD","SG9999002562.SGD","LU0417516738.SGD","LU0348825331.USD","BK1589","LU1688375341.USD","IE00B0JY6N72.USD","LU1880383366.USD","LU0856984785.SGD","LU0359201612.USD","BK1576","LU0307460666.USD","LU0572944931.SGD","LU0359202008.SGD","LU0456846285.SGD","LU0320764599.SGD","LU0327786744.USD","LU3063872942.SGD","LU0979878070.USD","LU1794554557.SGD","LU0043850808.USD","LU0823426308.USD","LU0456827905.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180496329","title":"药明生物6月30日回购289万股股份，累计回购逾3710.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180496329","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180496329?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:23","pubTimestamp":1782829394,"startTime":"0","endTime":"0","summary":"2026年6月30日，药明生物技术有限公司披露翌日报表。公告显示，药明生物当日于香港联交所场内回购2,890,000股普通股，约占回购前已发行股本的0.06976%，每股购回价介乎港币34.22元至34.64元，合计耗资约9,982.51万港元。公司自2026年5月26日至6月30日已在市场上累计回购37,108,000股股份，总代价约11.72亿港元。药明生物表示，此次股份回购及新增发行已根据董事会正式授权，并已遵守香港联交所证券上市规则及所有适用法律与监管规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物6月30日回购289万股股份，累计回购逾3710.8万股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647325211","title":"港股异动 | CRO概念股涨幅居前 长期看AI将引发行业变革 研发端或分化而生产端整体受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2647325211","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647325211?lang=zh_cn&edition=full","pubTime":"2026-06-29 14:28","pubTimestamp":1782714533,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0516422952.EUR","LU1794554557.SGD","LU0140636845.USD","LU0856984785.SGD","LU1880383366.USD","BK1521","BK1583","LU0819121731.USD","LU0417516902.SGD","LU0979878070.USD","LU0052750758.USD","LU1688375341.USD","LU0516422440.USD","LU0359201612.USD","06127","LU2242644610.SGD","LU0708995583.HKD","LU0456827905.SGD","LU0823426480.USD","LU0051755006.USD","06821","LU2045819591.USD","SG9999002463.SGD","LU3063872942.SGD","LU1046422090.SGD","LU0516422366.SGD","LU1242518857.USD","LU0417516738.SGD","LU2125910500.SGD","LU0348766576.USD","SG9999002562.SGD","LU0572944931.SGD","BK1191","BK1589","LU0456846285.SGD","LU0588546209.SGD","LU0043850808.USD","LU0359202008.SGD","LU0516423174.USD","LU0516423091.SGD","LU0039217434.USD","02359","LU0327786744.USD","LU0823426308.USD","LU2039709279.SGD","02269","LU0307460666.USD","IE00B0JY6N72.USD","LU0326950275.SGD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159164688","title":"港股生物医药板块反弹，荣昌生物涨超16%，创新药主线全面爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=1159164688","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159164688?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:55","pubTimestamp":1782701710,"startTime":"0","endTime":"0","summary":"6月29日，港股生物医药股集体走强，荣昌生物涨超16%，康诺亚-B、诺诚健华、康方生物均涨超12%。板块上涨主要受创新药出海、BD交易活跃及临床管线进展预期带动，资金加速回流创新药和CXO方向。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","03347","09969","02269","09995","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":0.2008},{"period":"3month","weight":0.0027},{"period":"6month","weight":-0.067},{"period":"1year","weight":0.4004},{"period":"ytd","weight":0.187}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.0204},{"period":"3month","weight":-0.0641},{"period":"6month","weight":-0.1032},{"period":"1year","weight":0.0031},{"period":"ytd","weight":-0.0553}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.666667,"avgChangeRate":0.061606},{"month":7,"riseRate":0.7,"avgChangeRate":0.081184},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}